Erudio Healtherudio.com
Drug
Epcoritamab trials: what clinicians said in public
HCP commentary reports on 2 clinical trials studying epcoritamab: EPCORE DLBCL-1 and EPCORE DLBCL-2. Each covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 4 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| EPCORE DLBCL-1 NCT04628494 · Genmab | relapsed/refractory diffuse large B-cell lymphoma | Phase 3 | 213 | 26 | Standard | Nov 13, 2026 | Preview |
| EPCORE DLBCL-2 NCT05578976 · Genmab | newly diagnosed diffuse large B-cell lymphoma | Phase 3 | 187 | 55 | Standard | Oct 31, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| EPCORE FL-1 NCT05409066 · Genmab DeepView → | relapsed or refractory follicular lymphoma | Phase 3 | Deep | View | |||
| EPCORE NHL-2 NCT04663347 · Genmab DeepView → | B-cell non-Hodgkin lymphoma | Phase 1/Phase 2 | Deep | View | |||
| EPCORE DLBCL-3 NCT05660967 · Genmab StandardView → | first-line anthracycline-ineligible diffuse large B-cell lymphoma | Phase 2 | Standard | View | |||
| EPCORE NHL-1 NCT03625037 · Genmab FocusedView → | relapsed or refractory B-cell non-Hodgkin lymphoma | Phase 1/Phase 2 | Focused | View | |||